Treatment response details among patients with myelofibrosis with myeloid metaplasia receiving lenalidomide therapy at either the Mayo Clinic (n = 27) or M. D. Anderson Cancer Center (MDACC; n = 41)
. | No. patients (%) . | . | . | ||
|---|---|---|---|---|---|
. | Combined . | Mayo Clinic . | MDACC . | ||
| Response*in anemia if baseline hemoglobin level below 100 g/L | 10 of 46 (22) | 6 of 27 (22) | 4 of 19 (21) | ||
| Major | 8 (17) | 4 (15) | 4 (21) | ||
| Minor | 2 (4) | 2 (7) | 0 (0) | ||
| Response*in palpable splenomegaly | 14 of 42 (33) | 6 of 22 (27) | 8 of 20 (40) | ||
| Major | 1 (2) | 1 (5) | 1 (5) | ||
| Minor | 13 (31) | 5 (23) | 7 (35) | ||
| Response* in thrombocytopenia if baseline platelet count less than 100 × 109/L | 6 of 12 (50) | NA | 6 of 12 (50) | ||
| Response* in hypercatabolic symptoms | 4 of 10 (40) | 4 of 10 (40) | NA | ||
| More than 25% decrease in serum LDH | 39 of 59 (66) | 18 of 27 (67) | 21 of 32 (66) | ||
| LDH normalized | 20 (34) | 8 (30) | 12 (38) | ||
. | No. patients (%) . | . | . | ||
|---|---|---|---|---|---|
. | Combined . | Mayo Clinic . | MDACC . | ||
| Response*in anemia if baseline hemoglobin level below 100 g/L | 10 of 46 (22) | 6 of 27 (22) | 4 of 19 (21) | ||
| Major | 8 (17) | 4 (15) | 4 (21) | ||
| Minor | 2 (4) | 2 (7) | 0 (0) | ||
| Response*in palpable splenomegaly | 14 of 42 (33) | 6 of 22 (27) | 8 of 20 (40) | ||
| Major | 1 (2) | 1 (5) | 1 (5) | ||
| Minor | 13 (31) | 5 (23) | 7 (35) | ||
| Response* in thrombocytopenia if baseline platelet count less than 100 × 109/L | 6 of 12 (50) | NA | 6 of 12 (50) | ||
| Response* in hypercatabolic symptoms | 4 of 10 (40) | 4 of 10 (40) | NA | ||
| More than 25% decrease in serum LDH | 39 of 59 (66) | 18 of 27 (67) | 21 of 32 (66) | ||
| LDH normalized | 20 (34) | 8 (30) | 12 (38) | ||
NA indicates either not applicable or not available.
Response criteria. Anemia: Patients who entered the study as transfusion dependent needed to maintain response for at least 3 months. Transfusion-independent patients needed to maintain response for at least 1 month to be considered responses. Major indicates normalization of hemoglobin; minor means either becoming transfusion independent or having an increase of at least 20 g/L in hemoglobin. Spleen: Patients needed to maintain response for at least 1 month to be considered responses. Major indicates either becoming nonpalpable if baseline is palpable at more than 5 cm in maximum distance below left costal margin (LCM) or more than a 50% decrease if baseline is at least 10 cm palpable below LCM. Minor means either more than a 50% decrease if baseline is less than 10 cm from LCM or more than a 30% decrease if baseline is at least 10 cm from LCM. Thrombocytopenia: Response indicates greater than 50% increase from baseline and an absolute count of 50 × 109/L. Hypercatabolic symptoms: Patients needed to maintain response for at least 1 month to be considered responses. Response indicates complete resolution in patients with baseline fever, weight loss, or drenching night sweats.